加载中
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
NASDAQHealthcareBiotechnology
最新数据
US$16.38
−US$0.77 · -4.49%
常规交易时段
US$16.38
−US$0.77 · -4.49%
盘中时间采用ET。市场数据可能有所延迟。
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
日内区间
当前US$16.38
52周区间
当前US$16.38
| 项目（USD） | 2025财年 |
|---|---|
| 研究与开发 | 6631.3万 USD |
| 销售、一般及管理费用 | 2098.1万 USD |
| 营业费用 | 8729.4万 USD |
| 利息收入 | 1140.3万 USD |
| 折旧和摊销 | 140.5万 USD |
| 营业利润 | −8729.4万 USD |
| 净利润 | −7488.1万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$43.00
上涨空间 162.52%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1009.65万0.00%2.3万亿 USD0.03%US$380.9-0.18%
iShares Russell 2000 ETFIWM603.17万0.01%787.4亿 USD0.19%US$276.36-0.55%
Vanguard Extended Market ETFVXF396.79万0.00%954亿 USD0.05%US$231.95-0.67%
AdvisorShares Psychedelics ETFPSIL149.78万3.27%4574.2万 USD1.84%US$20.63-2.92%
Schwab U.S. Small-Cap ETFSCHA132.52万0.01%217.13亿 USD0.03%US$32.49-0.52%
iShares Russell 2000 Growth ETFIWO132.48万0.01%139.17亿 USD0.24%US$350.99-0.77%
ALPS Medical Breakthroughs ETFSBIO116.6万0.62%1.87亿 USD0.50%US$52.585-2.35%
iShares Russell 2000 Value ETFIWN84.91万0.01%137.49亿 USD0.24%US$210.48-0.29%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFAdvisorShares Psychedelics ETFPSILSchwab U.S. Small-Cap ETFSCHAiShares Russell 2000 Growth ETFIWOALPS Medical Breakthroughs ETFSBIOiShares Russell 2000 Value ETFIWNAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
